- General information enquiries
- Call 00 800 6 7 8 9 10 11
- E-mail your questions
European Commission
Public Health
Accessibility tools
Service tools
Language selector
- Current languageen
Navigation path
- European Commission
- Public health
- Reference documents
- Register
- Orphan products
- Lutetium-177(3+),S2,S7-cyclo[N-{4,7,10
Pharmaceuticals - Community Register
Community register of orphan medicinal products | GRANTED |
Product information |
Lutetium-177(3+),S2,S7-cyclo[N-{4,7,10-tricarboxymethyl-1,4,7,10-tetraaza-cyclododecan-1-yl-acetyl}-4-chloro-L-phenylalanyl-D-cysteinyl-4-[(4S)-2,6-dioxo-1,3-diazinane-4-carboxamido]-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-lysyl-L-threonyl-L-cysteinyl-D-tyrosinamide]
| EU orphan designation number: | EU/3/16/1754
|
| Active ingredient: | Lutetium-177(3+),S2,S7-cyclo[N-{4,7,10-tricarboxymethyl-1,4,7,10-tetraaza-cyclododecan-1-yl-acetyl}-4-chloro-L-phenylalanyl-D-cysteinyl-4-[(4S)-2,6-dioxo-1,3-diazinane-4-carboxamido]-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-lysyl-L-threonyl-L-cysteinyl-D-tyrosinamide] |
| Indication: | Treatment of gastro-entero-pancreatic neuroendocrine tumours |
| Sponsor: | Ipsen Pharma
65 quai Georges Gorse, F-92100 Boulogne-Billancourt, France |
Public summary of scientific opinion
European Commission procedures |
| Close date procedure | Procedure type | EMEA number | Decision | summary publ | decision docs | annex |
| 18/10/2016 | Orphan designation | EMA/OD/089/16 | (2016)6745 of 14/10/2016 |
CONTACT
EU links
Directorate General Health & Consumers